2012
Development and characterization of an isogenic cell line with a radioresistant phenotype
de Llobet L, Baro M, Figueras A, Modolell I, Da Silva M, Muñoz P, Navarro A, Mesia R, Balart J. Development and characterization of an isogenic cell line with a radioresistant phenotype. Clinical And Translational Oncology 2012, 15: 189-197. PMID: 22855182, DOI: 10.1007/s12094-012-0898-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisBlotting, WesternCarcinoma, Squamous CellCell CycleCell MovementCell ProliferationDose-Response Relationship, RadiationFemaleFlow CytometryGamma RaysHumansHyaluronan ReceptorsMiceMice, NudePhenotypeRadiation ToleranceTumor Cells, CulturedVascular Endothelial Growth Factor AWound HealingXenograft Model Antitumor AssaysConceptsCell linesIsogenic cancer cell linesIsogenic cell linesRadiation-induced DNA fragmentationCancer cellsSpecific cell functionsDNA repair abilityBiological traitsAppropriate study modelsCell cycle distributionVascular endothelial growth factor (VEGF) secretionMolecular characterizationCell survivalDNA fragmentationRadioresistant phenotypeCell growthCancer cell linesSecretion of VEGFGrowth factor secretionSingle cellsCycle distributionCell functionRepair abilityRadiation resistanceWestern blot
2010
Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy
Pueyo G, Mesia R, Figueras A, Lozano A, Baro M, Vazquez S, Capella G, Balart J. Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy. The Oncologist 2010, 15: 976-986. PMID: 20798193, PMCID: PMC3228040, DOI: 10.1634/theoncologist.2008-0290.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorKi-67 indexMicrovessel densityAggressive phenotypeTumor growthHigh Ki-67 indexCetuximab maintenance therapyMicroscopic residual diseaseBenefits of radiotherapyVascular endothelial growth factor (VEGF) secretionUntreated cellsGrowth factor secretionMechanism of actionCetuximab maintenanceGrowth factor receptorMaintenance therapyAdjuvant therapyPreclinical rationaleMaintenance treatmentResidual diseaseCarcinoma cell linesClinical evaluationExtracellular signal-related kinaseIrradiated cellsCetuximab